CERITINIB FOR NON-SMALL CELL LUNG CANCER: UNDERSTANDING AND MANAGING ADVERSE REACTIONS FROM THERAPY TARGETING ANAPLASTIC LYMPHOMA KINASE

Kreamer Kristen; Riordan Debbie

首页> 外文期刊>Oncology nursing forum >CERITINIB FOR NON-SMALL CELL LUNG CANCER: UNDERSTANDING AND MANAGING ADVERSE REACTIONS FROM THERAPY TARGETING ANAPLASTIC LYMPHOMA KINASE

【24h】

CERITINIB FOR NON-SMALL CELL LUNG CANCER: UNDERSTANDING AND MANAGING ADVERSE REACTIONS FROM THERAPY TARGETING ANAPLASTIC LYMPHOMA KINASE

机译：CERITINIB用于非小细胞肺癌：理解和处理靶向靶向再生性淋巴瘤激酶的治疗的不良反应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology nursing forum》 |2015年第2期|共1页
作者
Kreamer Kristen; Riordan Debbie;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类护理学;
关键词

相似文献

外文文献
中文文献
专利

1. CERITINIB FOR NON-SMALL CELL LUNG CANCER: UNDERSTANDING AND MANAGING ADVERSE REACTIONS FROM THERAPY TARGETING ANAPLASTIC LYMPHOMA KINASE [J] . Kreamer Kristen, Riordan Debbie Oncology nursing forum . 2015,第2期

机译：CERITINIB用于非小细胞肺癌：理解和处理靶向靶向再生性淋巴瘤激酶的治疗的不良反应
2. Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong [J] . Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Cost Effectiveness Resource Allocation . 2020,第1期

机译：Ceritinib与克里齐替尼在预先治疗的促进性淋巴瘤激酶（ALK） - 阳性非小细胞肺癌（NSCLC）中的成本效果分析
3. Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer [J] . Maobai Liu, Longfeng Zhang, Qishu Huang, Cancer Management and Research . 2019,第4期

机译：Ceritinib和Alectinib对屈曲胰蛋白酶阳性淋巴结激酶阳性高级非小细胞肺癌的成本效果分析
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma. [D] . Pearson, Joel Dylan. 2013

机译：了解JunB转录因子在间变性淋巴瘤激酶阳性，间变性大细胞淋巴瘤中的功能。
6. PCN33 Cost-Effectiveness of Ceritinib Versus Current Therapies for Chemotherapy-Experienced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients in Mexico [O] . Balu S, Cerezo-Camacho O, Smith NJ, 2015

机译：墨西哥的Ceritinib与目前的疗法相比，PCN33的成本效益-墨西哥有化疗经验的间变性淋巴瘤激酶阳性的非小细胞肺癌患者

CERITINIB FOR NON-SMALL CELL LUNG CANCER: UNDERSTANDING AND MANAGING ADVERSE REACTIONS FROM THERAPY TARGETING ANAPLASTIC LYMPHOMA KINASE

著录项

相似文献

相关主题

期刊订阅